UBS Group AG Has $8.14 Million Stock Position in Janux Therapeutics, Inc. $JANX

Posted by Geri Gentry on May 18th, 2026

UBS Group AG increased its stake in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 51.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 590,060 shares of the company’s stock after purchasing an additional 199,703 shares during the period. UBS Group AG’s holdings in Janux Therapeutics were worth $8,143,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Janux Therapeutics by 10.4% in the third quarter. Vanguard Group Inc. now owns 2,417,104 shares of the company’s stock worth $59,074,000 after purchasing an additional 227,676 shares during the period. Orbimed Advisors LLC increased its position in shares of Janux Therapeutics by 45.9% in the third quarter. Orbimed Advisors LLC now owns 1,766,100 shares of the company’s stock worth $43,163,000 after purchasing an additional 555,800 shares during the period. Readystate Asset Management LP increased its position in shares of Janux Therapeutics by 38.0% in the third quarter. Readystate Asset Management LP now owns 960,379 shares of the company’s stock worth $23,472,000 after purchasing an additional 264,423 shares during the period. Prosight Management LP increased its position in shares of Janux Therapeutics by 1.3% in the third quarter. Prosight Management LP now owns 865,350 shares of the company’s stock worth $21,149,000 after purchasing an additional 11,446 shares during the period. Finally, Bank of America Corp DE increased its position in shares of Janux Therapeutics by 14.7% in the second quarter. Bank of America Corp DE now owns 859,423 shares of the company’s stock worth $19,853,000 after purchasing an additional 110,097 shares during the period. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Price Performance

Shares of JANX stock opened at $13.89 on Monday. Janux Therapeutics, Inc. has a twelve month low of $12.12 and a twelve month high of $35.34. The company has a market cap of $847.01 million, a P/E ratio of -7.55 and a beta of 2.58. The business has a fifty day simple moving average of $14.42 and a 200 day simple moving average of $16.95.

Janux Therapeutics (NASDAQ:JANX – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.13. The business had revenue of $3.73 million for the quarter, compared to the consensus estimate of $4.36 million. As a group, equities research analysts anticipate that Janux Therapeutics, Inc. will post -1.71 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently commented on JANX. Guggenheim decreased their price target on Janux Therapeutics from $68.00 to $58.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. UBS Group cut Janux Therapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $57.00 to $15.00 in a research report on Wednesday, April 15th. Evercore set a $22.00 price target on Janux Therapeutics in a research report on Monday, May 11th. Barclays cut Janux Therapeutics from an “overweight” rating to an “underweight” rating and decreased their price target for the stock from $29.00 to $14.00 in a research report on Monday, April 20th. Finally, JonesTrading decreased their price target on Janux Therapeutics from $50.00 to $28.00 and set a “buy” rating on the stock in a research report on Tuesday, April 28th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $45.85.

Read Our Latest Report on JANX

Insider Buying and Selling at Janux Therapeutics

In related news, VP Maria Dobek sold 2,038 shares of the company’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $14.17, for a total transaction of $28,878.46. Following the completion of the sale, the vice president directly owned 32,270 shares in the company, valued at $457,265.90. This represents a 5.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 7.90% of the stock is currently owned by corporate insiders.

About Janux Therapeutics

(Free Report)

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.